Exactech (EXAC) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Exactech 2015 Revenue $241.8 Million, Net Income $14.8 Million, EPS $1.04
February 16, 2016 4:05 PM ESTQ4 Revenue $62.7M, Net Income $4.1M, EPS $0.29
GAINESVILLE, Fla.--(BUSINESS WIRE)-- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for extremities, knee, hip, spine and biologics, announced today that revenue for 2015 decreased 3% to $241.8 million from $248.4 million in 2014 and 2015 revenue increased 1% on a constant currency basis. Diluted earnings per share for the year was $1.04 based on net income of $14.8 million, representing a 10% decrease compared to net income of $16.5 million or $1.18 diluted earnings per share during 2014.
2015 Full Year Highlights and Segment Performance
Extremity implant... More
